SMITHKLINE BEECHAM PHARMACEUTICALS - A SPURT FROM THE STARTING BLOCKS
Article Abstract:
SmithKline Beecham Pharmaceuticals (India) Limited (SBP), the Indian subsidiary of SmithKline Beecham Plc of UK, has announced a bonus in the ratio of 1:1 to its shareholders for the year ended December 1997. Its sales and other income increased by 30.70 percent in 1997. Its net profit rose by 70 percent. In the total equity of SMPL, the UK parent has a stake of 40 percent, the foreign institutional investors 5 percent, Indian institutions 23 percent and the Indian public the rest. Of the total 30 products under its portfolio, the 7 major earners are 2 antibiotics (Augmentin and Timentin), the hepatitis-B vaccine (EngerisB), Zentel, Fefol-Z, Bactroban and Iodex. These 7 products account for 85-90 percent of the total sales of SBP. (gsh) ------------------------------------------------------------ Financial results of SmithKline Beecham Pharmaceuticles (India) Limited ------------------------------------------------------------ Particulars Year ending December (Rs in crore) 1997 1996 ------------------------------------------------------------ Sales 259.50 201.99 ------------------------------------------------------------ Income 270.60 208.62 ------------------------------------------------------------ Operating profit 53.40 35.54 ------------------------------------------------------------ Interest 0.52 0.79 ------------------------------------------------------------ Depreciation 1.71 1.72 ------------------------------------------------------------ Net profit 33.18 19.33 ------------------------------------------------------------ Equity 14.70 14.70 ------------------------------------------------------------ EPS (Rs) 22.58 13.15 ------------------------------------------------------------ Net worth 124.82 99.72 ------------------------------------------------------------
Comment:
Announces bonus in ratio of 1:1 to its shareholders for yr ended 12/97, & reports 30.7% increase in sales & other income in 1997
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
SMITHKLINE NET STAGNANT IN 1998, TO PAY 30%
Article Abstract:
Smithkline Beecham Pharmaceuticals has posted a net profit of Rs33.26 crore for the calendar year 1998 (Rs33.18 crore in the calendar year 1997). The company has recommended a 30 percent dividend for 1998. Its net sales increased by 20 percent to Rs308.87 crore (Rs259.59 crore). It recorded a total expenditure of Rs270.68 crore (Rs217.17 crore). (gs)(vr)
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
SMITHKLINE BEECHAM PHARMACEUTICALS
Article Abstract:
Smithkline Beecham Pharmaceuticals of Bangalore has announced its audited financial results for the year ended December 31, 1998. The Board of Directors have proposed a dividend of 30 percent on the enhanced share capital for the year ended December 31, 1998. (uh)(vr)
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: NARMADA CEMENT REPORTS Rs5.83-CR LOSS NARMADA CEMENTS POSTS LOSS. NARMADA CEMENT COMPANY LIMITED: A BREATH OF FRESH AIR
- Abstracts: BPCL REGISTERS 23% RISE IN NET BPCL H1 NET SALES UP. BPCL TO EXPAND CAPACITY TO 10 M TONNES
- Abstracts: FAILING TO ENTHUSE INVESTORS: ESSAR STEEL LTD ESSAR STEEL NOT TO PAY DIVIDEND FAILING TO ENTHUSE INVESTORS: CMC Ltd